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Available online 27 November 2015Persistence of latently infected cells in presence of Anti-Retroviral Therapy presents themain obstacle toHIV-1 erad-
ication. Much effort is thus placed on identiﬁcation of compounds capable of HIV-1 latency reversal in order to ren-
der infected cells susceptible to viral cytopathic effects and immune clearance. We identiﬁed the BAF chromatin
remodeling complex as a key player required for maintenance of HIV-1 latency, highlighting its potential as a mo-
lecular target for inhibition in latency reversal. Here,we screened a recently identiﬁedpanel of smallmolecule inhib-
itors of BAF (BAFi's) for potential to activate latent HIV-1. Latency reversal was strongly induced by BAFi's Caffeic
Acid Phenethyl Ester and Pyrimethamine, twomolecules previously characterized for clinical application. BAFi's re-
versedHIV-1 latency in cell line based latencymodels, in two ex vivo infected primary cellmodels of latency, aswell
as in HIV-1 infected patient's CD4+ T cells, without inducing T cell proliferation or activation. BAFi-induced HIV-1
latency reversal was synergistically enhanced upon PKC pathway activation and HDAC-inhibition. Therefore BAFi's
constitute a promising family of molecules for inclusion in therapeutic combinatorial HIV-1 latency reversal.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article underimportant insights into the characteristics and dynamics of the persis-
tent latent pool of the HIV-1 virus in infected patients (Pierson et al.,
2000; Dahabieh et al., 2015; Geeraert et al., 2008; Chun et al., 1995,
2007). Studies have led to the identiﬁcation of quiescent latently infect-
ed CD4+ memory T cells, which harbor latent HIV-1, as the major
barrier to a cure (Finzi et al., 1999; Siliciano et al., 2003). The majority
of HIV-1 infected patients are diagnosed during the chronic phase of
the infection, when a large reservoir of latently infected cells is already
established (Strain et al., 2005; Watanabe et al., 2011; Whitney et al.,
2014). Therefore, to achieve a functional cure, recent pharmacological
efforts have centered on targeting the reservoir harboring latent HIV-
1 for activation in order to induce viral replication. As a second step,
following latency reversal, the infected cells would be exposed to viral
cytopathic effects and the immune system, thereby eliminating or
depleting the infected cells that constitute the latent reservoir (Deeks,
2012).
Latently HIV-1 infected cells harbor replication competent HIV-1
virus, whose gene expression is transcriptionally blocked. Once inte-
grated, the double stranded HIV-1 provirus behaves as a cellular gene
and becomes subject to a complex network of molecular mechanisms
that determine its transcriptional state (Mbonye and Karn, 2014;
Mahmoudi, 2012; Dahabieh et al., 2015). As part of the genome, thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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organized into speciﬁcally deposited nucleosomes: in its latent state,
the 5'LTR is organized into nuc-0 and nuc-1, two strictly positioned
nucleosomes that are separated by DHS1, a region sensitive to nuclease
digestion, which encompasses a loosely positioned nucleosome
(Verdin, 1991; Verdin and Van Lint, 1995; Rafati et al., 2011). The posi-
tioning of nuc-1, downstream of the core promoter transcription start
site, is the hallmark of the repressed 5′ LTR. Upon activation, nuc-1
becomes rapidly and speciﬁcally disrupted, allowing for HIV-1 gene ex-
pression to occur (Verdin and Van Lint, 1995; Verdin et al., 1993; Van
Lint et al., 1996; Rafati et al., 2011).
The chromatin structure of the HIV-1 promoter, as with cellular
promoters, is generated through the concerted activity of protein
complexes, which remodel chromatin (Mbonye and Karn, 2014; Lusic
and Giacca, 2015). This is in part accomplished by loosening or
tightening histone-DNA interaction via posttranslational modiﬁcations
on histone tails, which include acetylation and methylation (Zentner
and Henikoff, 2013). Of particular interest for regulation of HIV-1 tran-
scription, histone deacetylases have been shown to play a critical role
in repressing gene expression at the HIV-1 LTR (Van Lint et al., 1996;
Keedy et al., 2009; Marban et al., 2007; Williams et al., 2006; Barton
and Margolis, 2013; Barton et al., 2014; Lu et al., 2014) and represent
an important target for therapies aimed at activation of latent virus
or latency reversal. Accordingly, a number of small molecule HDAC in-
hibitors including valproic acid (Edelstein et al., 2009), suberoylanilide
hydroxamic acid (SAHA) (Contreras et al., 2009), Panobinostat
(Rasmussen et al., 2013), and Romidepsin (Wei et al., 2014) have
been or are currently under clinical investigation for their potential in
therapeutic HIV-1 latency reversal (Archin et al., 2012, 2014; Elliott
et al., 2014; Barton et al., 2015; Rasmussen et al., 2014).
Initial data from preclinical and clinical studies using HDAC inhibi-
tors in therapeutic latency reversal suggest that while promising,
HDAC inhibitors alone may not be sufﬁcient in activation of the latent
HIV-1 to the extent required to accomplish clinically signiﬁcant deple-
tion of the latent reservoir in patients. HIV-1 transcriptional latency is
a complex molecular phenomenon, driven and controlled by multiple
mechanisms, including the position of virus integration in the genome,
its orientation and proximity to endogenous genes, and the presence
and activity of host transcription factors and cofactors on the HIV-1
promoter (Van Lint et al., 2013; Dahabieh et al., 2015; Mbonye and
Karn, 2014; Ruelas and Greene, 2013; Matsuda et al., 2015). Therefore,
the speciﬁc transcriptional environment of each latently infected cell
is likely to impact its responsiveness to activatingmolecules. According-
ly, the molecular mechanisms at play in transcriptionally silencing the
latent reservoir are likely to be diverse and heterogeneous. Indeed,
data obtained from in vitro models using latently infected cell lines
support the notion that targeting two ormore pathways in combination
is more effective in activating latent HIV-1 by inducing synergistic
activation of the latent promoter (De Crignis and Mahmoudi, 2014;
Laird et al., 2015). It is therefore critical to identify and target multiple
molecular effectors with distinct mechanisms that drive HIV-1 latency
in order to obtain more effective and synergistic activation of the latent
reservoir.
ATP dependent chromatin remodeling complexes are another
group of factors, which the cell has co-evolved in addition to post-
translational histone modiﬁcations, in order to alter histone-DNA con-
tacts and change chromatin structure. These multi-subunit protein
complexes use energy from ATP hydrolysis to disrupt or move nucleo-
somes, thereby remodeling chromatin and modulating access to DNA
(Narlikar et al., 2013; Petty and Pillus, 2013; Hargreaves and Crabtree,
2011; Mahmoudi and Verrijzer, 2001). We have recently found that
the BAF chromatin remodeling complex uses energy from ATP hydroly-
sis to position the transcriptionally repressive nuc-1 over thermody-
namically sub-optimal DNA sequences leading to the establishment
and maintenance of HIV-1 latency. Consistent with the pivotal role of
BAF complex in HIV-1 latency, we have shown that siRNA mediateddepletion of BAF speciﬁc subunits signiﬁcantly decreases the percentage
of latent events at the time of infection. Similarly, in cells inwhich laten-
cy is already established, such as in vitro T cell line models of latency,
depletion of BAF subunits results in reactivation of latent virus. Our
data identiﬁed the BAF chromatin remodeling complex as a putative
molecular target in therapeutic efforts aimed at HIV-1 latency reversal
(Rafati et al., 2011; Mahmoudi, 2012). Recently, a spectrum of potential
smallmolecule inhibitors of the BAF complexwere identiﬁed in a screen
of more than 30,000 compounds, which included synthetic molecules,
natural products, drug-like compounds and molecules with known
bioactivity (Dykhuizen et al., 2012). 34 BAF inhibitors were initially
identiﬁed by monitoring mRNA expression of well characterized BAF
target genes in mouse embryonic stem cells. A second screen then
eliminated molecules with non-speciﬁc targets and general repressive
activities, leading to the identiﬁcation of 20 compounds that transcrip-
tionally mimic genetic deletion of BRG1 (the ATPase subunit of the
complex), indicating speciﬁc activity against the BAF complex.
Here we have tested a panel of BAF inhibitors for their potential to
activate latent HIV-1. Following the initial screening, we focused on
functional characterization of A01, A11, and C09, the three compounds
that displayedmost signiﬁcant activity on the latent LTRwith the lowest
toxicity. We found that BAF inhibitors (BAFi's) activate latent HIV-1 in
both Jurkat cell lines harboring latent full length HIV-1 and HIV-1
derived viruses, in two distinct ex vivo infected primary CD4+ T cell
models of HIV-1 latency, as well as in cells obtained from virologically
suppressed HIV-1 infected patients. BAFi-mediated activation of latent
HIV-1 was accompanied by the displacement of the BAF complex from
the HIV-1 LTR, as demonstrated by ChIP assay, and was synergistically
enhanced in presence of the HDAC inhibitor SAHA and the PKC agonist
Prostratin. Consistently, FAIRE assays demonstrated removal of the
repressive positioned nuc-1 in response to treatment with BAFi's, and
synergism at themolecular level when cells were co-treatedwith BAFi's
together with Prostratin.While efﬁciently activating latent HIV-1, treat-
ment with BAFi's did not induce T cell proliferation or general T cell ac-
tivation of primary CD4+ T cells. Our data identiﬁes BAFi's as a
promising family of small molecules for inclusion in therapeutic
combinations aiming to reverse HIV-1 latency.
2. Materials and Methods
2.1. Cell Culture and Reagents
Jurkat, J-Lat A2 (LTR-Tat-IRES-GFP), J-Lat 11.1 (integrated full-length
HIV-1 genome mutated in env gene and GFP replacing Nef) (Jordan
et al., 2001, 2003) cells were cultured in RPMI-1640 medium (Sigma
Aldrich, Zwijndrecht, The Netherlands) supplemented with 10% FBS
and 100 μg/ml penicillin-streptomycin at 37 °C in a humidiﬁed 95%
air-5% CO2 atmosphere. Cells were treated with the following com-
pounds: Phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich);
Ionomycin (Sigma Aldrich); SAHA-Vorinostat (Selleck Chemicals);
Prostratin (Sigma Aldrich); A01 (N-hydroxy-N′-phenyl-octanediamide
2-hydroxy-N′-[(E)-(5-hydroxy-6-oxocyclohexa-2,4-dien-1-ylidene)
methyl]benzohydrazide (BRD-K70161581-001-01-5), Vitas-M Labora-
tory, Ltd., Apeldoorn, Netherlands.); A11 (5-(4-chlorophenyl)-6-ethyl-
2,4-pyrimidinediamine (BRD-K88429204-001-18-7), Sigma Aldrich);
C09 (2-phenylethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate (BRD-
K91370081-001-04-6), MP Biomedicals, Eindhoven, The Netherlands).
2.2. Flow Cytometry
GFP expression in the J-Lat cell lines was analyzed by Flow Cytome-
try. The live population was deﬁned by forward versus side scatter
proﬁles. Cells were further gated by using forward scatter versus GFP in-
tensity to differentiate between GFP-positive and -negative cells.
In primary models of latency, the phenotypic characteristics of the
cell population at the moment of reactivation were determined using
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Breda, The Netherlands), anti-CCR7-PE (eBioscience, Uithoorn, The
Netherlands), anti-CD27-APC (Becton Dickinson), and anti CD45RO-
FITC (Dako, Heverlee, Belgium). Cells were stained for 30 min at 4 °C,
washed with PBS, and re-suspended for ﬂow cytometric analysis.
To determine cell activation following BAF complex inhibition, cells
were treated with BAFi's for 72 h. Untreated cells and PMA/Ionomycin
treated cells were used as negative and positive control, respectively.
At 24 and 72 h post treatment cells were collected and stained with
Fixable Viability Dye eFluor®450 and anti-CD25-PE (BectonDickinson).
Cellswere stained for 30min at 4 °C,washedwith PBS, and resuspended
for ﬂow cytometric analysis. To determine the expression of KI67, cells
were collected and stained with Fixable Viability Dye eFluor® 450 for
15 min. Following 2% PFA ﬁxation, cells were permeabilized with 0.3%
saponin for 30 min, incubated with anti-Ki67-PE (eBioscience)
antibody for 60 min at 4 °C, washed in PBS and resuspended for ﬂow
cytometry. All samples were analyzed with a Becton Dickinson Fortessa
instrument.
2.3. Primary CD4+ T Cell Isolation and Infection
Primary CD4+ T cells were isolated from buffy coats from healthy
donors by Ficoll gradient followed by magnetic separation with
EasyStep Human CD4+ T cell Enrichment kit (StemCells Technologies,
Grenoble, France).
Two in vitro models of HIV-1 latency were set up following the
method developed by Bosque and Planelles (Bosque and Planelles,
2009) and Lassen and Greene (Lassen et al., 2012). Infections were
performed using a pseudotyped virus expressing luciferase. Viral
pseudotyped particles were obtained by co-transfecting HXB2 Env
together with the HIV-1 backbone plasmid (pNL4.3.Luc.R-E-) into HEK
293 T cells using PEI (Polyethylenimine) transfection reagent. Twenty
four, 48 and 72 h post-transfection, the pseudovirus-containing
supernatant was collected, ﬁltered through a 0.45 μm ﬁlter, aliquoted,
and stored at−80 °C.
For generation of latently infected primary cells according to the
Bosque and Planelles method, puriﬁed CD4+ T cells were cultured in
RPMI 1640 containing 10% FBS in presence of 10 ng/ml) of TGF-β
(Sigma-Aldrich), 1 μg/ml α-IL4 (PeproTech, London, UK), 2 μg/ml α-
IL12 (PeproTech), and α-CD3-CD28 (Life Technologies, Breda, The
Netherlands) coated beads in 1:1 ratio for 3 days. After 3 days α-CD3-
CD28 coated beads were removed and cells were cultured in RPMI
1640 containing 10% FBS, 100 μg/ml penicillin-streptomycin and
5 ng/ml of IL2 (Sigma-Aldrich) for 4 days. On day 7 post stimulation
cells were infected with HIV-derived virus particles. Primary CD4+ T
cells, were infected with the PNL4.3.LUC.R-E- virus by spinoculation
(90 min at 1200 g), washed in PBS and cultured in RPMI 1640 contain-
ing 10% FBS, 100 μg/ml penicillin-streptomycin, IL2 (5 ng/ml) and
Saquinavir Mesylate (5 μM). Six days after infection cells were treated
with BAFi's in presence of Raltegravir (30 μM).
Generation of latently infected cells according to Lassen and Greene
methodwas performed as follows: CD4+ T cells were infectedwith the
PNL4.3.LUC.R-E- virus by spinoculation (120 min at 1200 g) right after
isolation and cultured for three days in RPMI 10% FBS and 100 μg/ml
penicillin-streptomycin in presence of Saquinavir Mesylate (5 μM).
Three days after infection cells were treated with BAFi's in presence of
Raltegravir (30 μM).
Cells were harvested 24 h after stimulation with BAF inhibitors,
washed once in PBS and luciferase activity was measured using
Luciferase Assay System (Promega, Leiden, The Netherlands). Relative
light units were normalized to protein content determined by Bradford
assay (Bio Rad, Veenendaal, The Netherlands).
HIV-1 molecular clone pNL4.3.Luc.R-E-, HIV-1 HXB2-Env expression
vector, Saquinavir Mesylate and Raltegravir were kindly provided
by the Centre for AIDS Reagents, NIBSC. HIV-1 molecular clone
pNL4.3.Luc.R-E- and HIV-1 HXB2-Env expression vector were donatedby Dr. Nathaniel Landau and Drs Kathleen Page and Dan Littman,
respectively.
2.4. Activation of HIV-1 Transcription in Patient CD4+ T Cells
Total PBMCs were obtained from HIV-infected patients without
(overt) clinical symptoms by leukapheresis, and isolated by Ficol
gradient density sedimentation. CD4+ T cells were isolated using the
CD4+T-Cell enrichment kit (Stem Cell Technologies) and frozen. Inclu-
sion criteria were as follows: age N 18 years; conﬁrmed HIV-1 infection;
plasma HIV-1 RNA viral load below 50 copies/ml for more than 12
months; cART for at least 3 years. 2.5 million CD4+ T cells were plated
in 6 wells plates in 2.5 ml of RPMI supplemented with 10% FBS and left
untreated or treated with 1 μM C09, 20 μM A11 or 300 nM Prostratin
alone or in combination as indicated. As a positive control, cells
were treated with CD3-CD28 beads or PMA-Ionomycin. Twelve hours
after stimulation cells were collected and lysed in RNA lysis buffer
(Promega). RNA was extracted and reverse transcribed using Random
primers (Life Technologies) and Superscript II (Life Technologies)
following manufacturer's instructions. Levels of cellular associated
RNA were quantiﬁed using a PCR targeting the HIV-1 POL gene. qPCR
was performed in a ﬁnal volume of 25 μl using 4 μl of cDNA, 2.5 μl of
10× PCR buffer (Life Technologies), 1.75 μl of 50 mMMgCl2 (Life Tech-
nologies), 1 μl of 10 mM dNTPs (Life Technologies), 0.125 μl of 100 μM
Pol For (HXB2 genome 4901→ 4924), 0.125 of 100 μM Pol Rev. (HXB2
genome 5060→ 5040), 0.075 μl of 50 μM of Pol Probe, and 0.2 μl Plati-
numTaq (Life Technologies). The lower limit of detection of thismethod
was of 20 copies of HIV-1 RNA in 1 μg of total RNA. The absolute number
of POL copies in PCR was calculated using a standard curves ranging
from 4 to 4 × 105 copies of a plasmid containing the full-length HIV-1
genome. The amount of HIV-1 cellular associated RNA was expressed
as number of copies/μg of input RNA in reverse transcription. Prepara-
tions of cell-associated RNA were tested for potential contamination
with HIV-1 DNA and-or host DNA by performing the PCR ampliﬁcation
in the presence and absence of reverse transcriptase.
This study was conducted in accordance with the ethical principles
of theDeclaration of Helsinki. The patients involved in the study provid-
ed signed informed consent and the study protocol was approved by
The Netherlands Medical Ethics Committee (MEC-2012-583).
2.5. Total RNA Isolation and Quantitative RT-PCR (RT-qPCR)
Total RNA was isolated from the cells using RealiaPrep RNA Cell
Miniprep System (Promega), cDNA synthesis was performed using
Superscript II Reverse Transcriptase (Life Technologies) kit following
manufactures protocol. RT-qPCR was performed using GoTaq qPCR
Master Mix (Promega) following manufacturer protocol. Ampliﬁcation
was performed on the CFX Connect Real-Time PCR Detection System
thermocycler (BioRad) using following thermal program starting with
3 min at 95 °C, followed by 40 cycles of 95 °C for 10 s and 60 °C for
30 s. Speciﬁcity of the RT-qPCR products was assessed by melting
curve analysis. Primers used for real-time PCR are listed in Table 1. Ex-
pression data was calculated using 2-ΔΔCt method by Livak Schmittgen
(Schmittgen and Livak, 2008). Cyclophyilin A (CycA) and ß-2-micro-
globulinwere used as housekeeping genes for J-Lat cell lines and prima-
ry cells, respectively.
2.6. Knock-down Experiments
Pre-designed siRNA pools targeting transcripts of the human ARID1a-
BAF250a (L-017,263-00-0005) and non-target control siRNA pool (D-
001,810-10-20) were purchased from Dharmacon (Dharmacon, Etten-
Leur, The Netherlands). Small-interfering RNAs were delivered by
nucleofection using Amaxa Nucleofector (Amaxa AG-Lonza, Cologne,
Germany) as previously described (Rafati et al., 2011). Brieﬂy, cells
were split to 3 × 105 cells/ml one day before nucleofection. Five million
Table 1
List of RT-qPCR primers.
Primer Sequence (5′-3′)
β – Actin For CGCAAAGACCTGTACGCCAAC
β – Actin Rev GAGCCGCCGATCCACACG
β2Microglobulin For AGCGTACTCCAAAGATTCAGGTT
β2Microglobulin Rev ATGATGCTGCTTACATGTCTCGAT
BAF250a For CTTCAACCTCAGTCAGCTCCCA (Wang et al., 2012)
BAF250a Rev GGTCACCCACCTCATACTCCTTT (Wang et al., 2012)
BRG-1 For GCAGGCTCGCATCGCACAC
BRG-1 Rev GCTCAATGGTCGCTTTGGTTCG
CycA (PPIA) For TCATCTGCACTGCCAAGACTG
CycA (PPIA) Rev CATGCCTTCTTTCACTTTGCC
Gag For AGTAGTGTGTGCCCGTCTGT
Gag Rev TCGCTTTCAGGTCCCTGTTCG
Gfp For GAAGCAGCACGACTTCTTCAA
Gfp Rev GCTTGTCGGCCATGATATAGA
IFNβ For GGAGGACGCCGCATTGAC
IFNβ Rev TGATAGACATTAGCCAGGAGGTTC
IL6 For CCCTGACCCAACCACAAATGC
IL6 Rev CAACAACAATCTGAGGTGCCCAT
IL10 For ACATCAAGGCGCATGTGAAC
IL10 Rev GCCACCCTGATGTCTCAGTT
Luc For TCTAAGGAAGTCGGGGAAGC (Barakat et al., 2011)
Luc Rev CCCTCGGGTGTAATCAGAAT (Barakat et al., 2011)
MIP26 For AGTGTGTGGCTCTTGATTTCTGAGG
MIP26 Rev CCACCTCCCTTGAGTCCCTTCTC
MMP9 For TGGTCCTGGTGCTCCTGGTG
MMP9 Rev GCTGCCTGTCGGTGAGATTGG
SOCS3 For CCAAGGACGGAGACTTCGAT
SOCS3 Rev GGTACTCGCTCTTGGAGCTG
TLR2 For TGGATGGTGTGGGTCTTGG
TLR2 Rev AGGTCACTGTTGCTAATGTAGG
Nuc-0 For ATCTACCACACACAAGGCTAC
Nuc-0 Rev GTACTAACTTGAAGCACCATCC
DHS-1 For AAGTTTGACAGCCTCCTAGC
DHS-1 Rev CACACCTCCCTGGAAAGTC
Nuc-1 For TCTCTGGCTAACTAGGGAACC
Nuc-1 Rev AAAGGGTCTGAGGGATCTCTAG
ChIP CTRL Reg For GCCAGAGTCAAGCCAGTAGTC
ChIP CTRL Reg Rev TAGCCTAATGTGGAGTGGATGTG
Alu For GCCTCCCAAAGTGCTGGGATTACAG
AluGag For GGTGCGAGAGCGTCAGTAT
AluGag Rev AGCTCCCTGCTTGCCCATA
AluGag probe [6FAM]AAAATTCGGTTAAGGCCAGGGGGAAAGAA[BHQ1]
ALB For TGCATGAGAAAACGCCAGTAA
ALB Rev ATGGTCGCCTGTTCACCAA
ALB probe [FAM]TGACAGAGTCACCAAATGATGCACAGAA[BHQ1]
Pol For GGTTTATTACAGGGACAGCAGAGA
Pol Rev ACCTGCCATCTGTTTTCCATA
Pol Probe [6FAM]ACTACTGCCCCTTCACCTTTCCAGAG[BHQ1]
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suspended in 100 μl of solution R, and nucleofected with 2 μM siRNA
using program O28. Nucleofected cells were re-suspended in 500 μl of
pre-warmed, serum-free antibiotic-free RPMI at 37 °C for 15 min and
then plated in 4 ml of pre-warmed complete media. Seventy-two hours
post-nucleofection cells were treated with SAHA [350 nM] or Prostratin
[100 nM]. LTR-driven GFP expression was assessed after 24 and 48 h
after treatment by FACS. RNA and protein for RT-qPCR and Western
blot analysis were isolated 96 h after nucleofection.2.7. Western blot Analysis
Cellswere treatedwith BAF inhibitors for 36 h and then lysedwith IP
buffer (25 mM HEPES, pH 7.9, 150 mM KCl, 1 mM EDTA, 5 mMMgCl2,
5% glycerol, 1% NP40, 0.5 mM dithiothreitol and a protease inhibitor
cocktail (Sigma Aldrich)) for 30 min on ice. Whole-cell protein lysate
was used for SDS-PAGE in order to detect BAF250a, BRG-1, INI-1, IκB,
and GAPDH. The following antibodies were used in Western blot
analysis: anti-SMARCA4-BRG1 (sc-17,796, Santa Cruz Biotechnology;
ab4081-100, Abcam), anti-ARID1a-BAF250a (kind gift from C.P.Verrijzer), anti-SMARCAB1-hSNF5 (ab4552, Abcam), anti- IκB (sc-371,
Santa Cruz Biotechnology) and anti-GAPDH (ab8245, Abcam). Signal
intensity for representative blots was quantiﬁed using ImageJ software
according to NIH guidelines. Brieﬂy, speciﬁc bands, related to protein
of interest were marked in order to generate plots of relative density.
Area under the plots, representing each band intensity, was normalized
to its loading control and then to its untreated sample for BAF250a and
INI-1, each band intensity for BRG-1 was normalized to its correspond-
ing loading control and to untreated control, band intensity of treated
samples for GAPDH was normalized with untreated controls.
2.8. Latency Establishment Experiment
HIV-derived virus particles were generated as described (Jordan
et al., 2001). Brieﬂy, HEK 293 T cells were transfected with VSVG, the
R8.9 packaging vector, and the retroviral vector LTR-Tat-IRES-EGFP
(pEV731). Viruswas harvested every 12 h starting at 24 h after transfec-
tion. Jurkat cells were treated with 1 μM BAFi's as indicated 1 h prior to
infection. Cells were then infected in presence or absence of BAFi's with
the LTR-Tat-IRES-EGFP virus at lowmultiplicity of infection (MOI), such
that approximately 10% of cells were infected. Ninety six hours after in-
fection, the GFP negative cell population was sorted using a FACSAria II
cell sorter (Becton Dickinson) and treated with PMA. Percentage of GFP
positive (latent) infections was determined by FACS analysis 48 h after
PMA stimulation.
For Alu-PCR, 2–5 ∙ 106 cells were subjected to genomic DNA isolation
using DNeasy Blood & Tissue Kit (Qiagen, Hilden, The Netherlands).
The following reaction mix was used for the ﬁrst round PCR: 1X PCR
buffer (Life Technologies), 1.5 mM MgCl2 (Life Technologies), 0.5 mM
dNTPs (Thermo Scientiﬁc,Waltham,MAUSA) 1 μMAlu forward primer,
6 μMGag reverse primer, 2.5 U of Platinium Taq polymerase (Life Tech-
nologies) and 150ng of genomicDNA. Ampliﬁcationwas performed in a
T100 Thermal Cycler (BioRad) with following thermal program: 2 min
at 95 °C, followed by 14 cycles of 95 °C for 30 s, 50 °C for 30 s and
72 °C for 210 s. A nested PCR targeting the Gag gene was performed
using the following reaction mix: 1 X PCR buffer, 1.5 mM MgCl2,
0.5 mM dNTPs, 0.5 μM AluGag For and AluGag Rev. primers, 0.15 μM
AluGag probe (FAM-AAAATTCGGTTAAGGCCAGGGGGAAAGAA-BHQ1),
1 U Platinium Taq polymerase and 3 ng of genomic DNA or 2 μl of Alu-
Gag PCR product. Ampliﬁcation was performed on the CFX Connect
Real-Time PCR Detection System thermocycler (BioRad) using follow-
ing thermal program starting with 5 min 95 °C, followed by 30 cycles
95 °C for 30 s, 60 °C for 30 s. Albumin gene was used for normalization.
Primer sequences used are listed in Table. 1.
2.9. Chromatin Immunoprecipitation (ChIP)
Eighteen hours prior to analysis J-Lat 11.1 cells were untreated or
treated with BAFi's as indicated. Twenty million cells were used per
sample. Cells were washed with PBS ++ (PBS, 1 mM CaCl2, 1 mM
MgCl2) and cross-linked for 30 min at room temperature by adding
buffer A (1% HCHO, 10 mM NaCl, 100 μM EDTA, 50 μM EGTA, 2 mM
HEPES pH 7.6). The reaction was quenched with 125 mM glycine.
Cross-linked cells were washed in ice-cold PBS ++ followed by washes
with buffer B (0.25% Triton-X 100, 1 mM EDTA, 0.5 mM EGTA, 20 mM
HEPES, pH 7.6) and buffer C (150 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 20 mM HEPES, pH 7.6) for 10 min at 4 °C. For sonication, cells
were re-suspended in ChIP incubation buffer (1% SDS, 1% Triton-X
100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES, pH 7.6,
Protease inhibitors cocktail) and chromatin was sheared by sonication
to an apparent length of ~500 bp using a Bio Ruptor sonicator (Cosmo
Bio Co., Ltd., Tokyo, Japan) with 20 times 60-s pulses at maximum
setting at 4 °C. At least 150 ul of each sample were collected for input.
Chromatin from approximately 20 million cells was diluted 7 times
with ChIP incubation buffer lacking SDS, in order to decrease SDS con-
centration in sonicated samples. Chromatin was immunoprecipitated
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Verrijzer or sc-32761, SantaCruz Biotechnology) and BSA-blocked
protein-A agarose beads (GE Healthcare) at 4 °C overnight. Beads were
washed twice with the following buffers buffer 1 (0.1% SDS, 0.1%
deoxycholate, 1% Triton-X 100, 150 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 20 mM HEPES pH 7.6), buffer 2 (0.1% SDS, 0.1% deoxycholate, 1%
Triton-X 100, 500 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM
HEPES pH 7.6), buffer 3 (250 mM LiCl, 0.5% deoxycho- late, 0.5% NP-40,
1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES, pH 7.6), and buffer 4 (1 mM
EDTA, 0.5 mM EGTA, 20 mM HEPES, pH 7.6). Immunoprecipitated
complexes and inputs were eluted in elution buffer (1% SDS, 0.1 M
NaHCO3) for 30 min at room temperature, and decrosslinked over-
night at 65 °C in presence of 200 mM NaCl2. DNA was extracted
with phenol:chloroform:isoamylalcohol 24:24:1 (Sigma) followed
by chroloform:isoamylalcohol 24:1 extraction, ethanol precipitated,
and resuspended in 100 μl H2O by shaking at 37 °C. Input and
immunoprecipitated DNA were subjected to Sybergreen qPCR cycles
with speciﬁc primers (sequences provided in Table. 1) with an CFX
Connect Real-Time PCR Detection System thermocycler (BioRad)
and GoTaq qPCR Mastermix (Promega).2.10. Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE)
Eighteen hours prior to analysis, J-Lat A2 and 11.1 cells were treated
with BAFi's where indicated. J-Lat cells were ﬁxed for 30 min by adding
formaldehyde to a ﬁnal concentration of 1% at room temperature.
Twenty million cells were used per FAIRE experiment. The reaction
was quenched with 125 mM glycine. Cross-linked cells were washed
with PBS followed by washes with buffer B (0.25% Triton-X 100, 1 mM
EDTA, 0.5 mM EGTA, 20 mM HEPES, pH 7.6) and buffer C (150 mM
NaCl, 1 mM EDTA, 0.5 mMEGTA, 20mMHEPES, pH 7.6). For sonication,
cells were re-suspended in ChIP incubation buffer (1% SDS, 1% Triton-X
100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES, pH 7.6)
and chromatin was sheared by sonication to an apparent length of
~200–400 bp (corresponding to ~100–200 bp of free DNA) using a
BioRuptor sonicator (Cosmo Bio Co., Ltd) with 20 times 30-s pulses
at maximum setting at 4 °C. Sonicated chromatin was twice
phenol:chloroform:isoamyl alcohol (24:24:1) extracted, washed with
chloroform:isoamylalcohol (24:1) and ethanol precipitated. Isolated
DNA was subjected to Sybergreen qPCR cycles with speciﬁc primers
(sequences provided in Table. 1) with a CFX Connect Real-Time PCR
Detection System (BioRad) and GoTaq qPCR Mastermix (Promega),
using following thermal program starting with 3 min at 95 °C, followed
by 40 cycles of 95 °C for 10 s and 60 °C for 30 s.2.11. Statistical Analysis
Data are shown as the average + S.D. of three or more independent
experiments. Statistical signiﬁcance for multiple comparisons was
calculated using Student's t test or, when appropriate, Mann–Whitney
non parametric test.
According to the Bliss independence method (Bliss, 1939),
threshold for synergism was calculated using the following equa-
tion μ(1+2)exp. = [1 − (1 – μ1) × (1− μ2)], where μ(1+2)exp. is the
expected percentage of cells reactivated after combinatorial treat-
ment in absence of synergism and μ1 and μ2 correspond to the per-
centage of cells reactivated by the single treatments. The difference
between the observed percentage of cells activated by combination
treatment and the expected percentage (μ(1+2)exp) describes the
interaction between two treatments. Combination was considered
synergistic if the difference and its 95% normal conﬁdence interval
(CI) were N0. Synergistic effect of BAFi's over SAHA + Prostratin
combination was calculated considering Prostratin + SAHA as a sin-
gle treatment.3. Results
3.1. Small Molecule Inhibitors of BAF Activate Latent HIV
We tested a panel of compounds (Figure S1 and Table S1), identiﬁed
in a screen for inhibitors of the BAF chromatin remodeling complex
(Dykhuizen et al., 2012) for their potential to activate latent HIV-1 in
J-Lat A2 (Fig. 1a) and J-Lat 11.1 (Fig. 1b) cells. These Jurkat clonal cell
lines contain, respectively, an integrated latent LTR-Tat-IRES-GFP virus
or a defective full-length HIV-1 genome expressing GFP in place of Nef
(Jordan et al., 2003). Six compounds signiﬁcantly activated the latent
HIV-1 in both cell lines, however 3 of these displayed signiﬁcant toxicity
at the concentrations tested in the screening. Therefore we focused on
A01, A11, and C09, the three BAF inhibitors displaying the strongest
capacity to activate latent HIV-1 while not signiﬁcantly affecting cell
viability. Titration experiments indicated optimal concentrations for
these compounds in HIV-1 activation to be in the 0.5–2 μM range in J-
Lat cell lines (Fig. 1c).
As the BAF inhibitors were identiﬁed in a screen in mouse ES cells,
we set out to conﬁrm their speciﬁcity in inhibition of the BAF complex
in human CD4+ T cells. Thus, we analyzed the gene expression proﬁle
of humanCD4+T cells after siRNAdepletion of the BAF-speciﬁc subunit
BAF250a and compared it with the gene expression proﬁle obtained
after treatment with BAFi's. J-Lat 11.1 cells were transfected with a
siRNA targeting the BAF250a subunit and the expression levels of the
LTR driven transcripts as well as those of endogenous BAF target
genes were analyzed by RT-qPCR 48 h after transfection. Depletion of
BAF250a was conﬁrmed by RT-qPCR and Western blot analysis
(Fig. 2a). As observed previously (Rafati et al., 2011), depletion of
BAF250a resulted in activation of latent HIV-1 as determined by an
increase in expression of the HIV-1 LTR-driven P24 and GFP reporter
(Fig. 2b). Moreover, qRT-PCR analysis identiﬁed a set of endogenous
previously described BAF target genes which were positively or nega-
tively modulated after BAF250a knock down. In particular, BAF250a
depletion induced the expression of IL10 (Wurster et al., 2012), and
SOCS3 (Dykhuizen et al., 2012), and decreased the expression of TLR2,
MMP9, IFNß, and IL6 (Barker et al., 2001; Ni and Bremner, 2007)
(Fig. 2b). To determine the level of activity and speciﬁcity of the BAFi's,
we examined the gene expression proﬁle of J-Lat11.1 cells 18 h after
treatment with A01, A11, and C09 (1 μM). Mirroring BAF250a
depletion, treatment with A11 and C09 upregulated IL-10 and SOCS3
while downregulating the expression of endogenous BAF target genes
TLR2,MMP9, INFβ, IL-6, whereas treatment with A01 resulted in signiﬁ-
cant down-regulation of MMP9 only, together with a signiﬁcant
upregulation of both IL-10 and SOCS3 (Fig. 2c). All BAFi's activated latent
HIV-1 as demonstrated by the increase in P24 and GFP expression
(Fig. 2c). Thus, inhibition of BAF with BAFi's functionally mimicked the
effect of siRNA depletion of BAF250a in modulating the expression of
endogenous BAF target genes and resulted in activation of the latent
HIV-1 as demonstrated by an increase in GFP and P24 expression.
To determine the direct effects of BAFi treatment on the latent HIV-1
promoter, we examined the BAF complex occupancy of the promoter by
ChIP assay. We have shown previously that, while bound to the latent
HIV-1 LTR, the BAF complex is displaced upon LTR activation (Rafati
et al., 2011). Similarly, as shown in Fig. 2d, the stimulation with the
BAFi's A11 and C09 results in the displacement of the BAF speciﬁc
subunit BAF250a, which is speciﬁcally enriched in the DHS1 and nuc-1
regions on the latent HIV-1 promoter. These results provide a direct
mechanistic evidence for the function of BAFi's in HIV-1 latency.
To investigate the mechanism mediating the activity of the BAFi's,
we analyzed the expression of the BAF subunits at the RNA and at the
protein level. To determine whether BAFi's directly affect the BAF
complex at the protein level, we quantitated the relative expression of
the BAF subunits BAF250a, BRG1, and INI-1 by Western blotting after
treatment with increasing concentrations of BAFi's (Figure S2a). Treat-
ment of cells for 36 h with increasing concentrations of A11 and C09
Fig. 1. Smallmolecule Inhibitors of the BAF complex (BAFi's) re-activate latent HIV. J-Lat A2 (Panel a) and 11.1 (Panel b) cellswere treatedwith BAFi's at 1 μMand 5 μMconcentrations and
re-activation quantitated at 24 and 48 h post treatment. Percent of GFP positive cells (left axes, dark colored bars), corresponding to the level of HIV-1 activation, and cell viability (right
axes light colored bars) were evaluated by FACS analysis. GFP levels of samples inwhich cell viability was below50% are not shown. HIV-1 activationwas considered signiﬁcantwhen GFP
levels exceeded the average + 2SD of untreated controls (red horizontal line). Red squares identify BAFi's which induced activation of HIV-1 without signiﬁcantly affecting cell viability.
These compounds were further investigated for their ability to activate HIV-1 transcription in 11.1 cells (Panel c). Data are presented as mean ± SD.
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levels, while not affecting the BRG1 and INI-1 subunits. We observed a
decrease of BAF250a levels of up to 50% after treatmentwith the highest
concentrations of A11,while C09 treatment resulted in a substantial (up
to 70%) decrease in BAF250a (Figure S2a). At the RNA level, the expres-
sion of BAF250a did not change in response to BAFi's (Figure S2b),
excluding an indirect mechanism whereby BAFi's treatment would
cause a decrease in transcription of the BAF subunits. Conversely, the
negative effect of A11 and C09 on stability of BAF250a is consistent
with a mechanism of direct inhibition, in which destabilization and
degradation of BAF250a at the protein level results in the speciﬁc inhibi-
tion of the BAF complex.
3.2. HIV-1 Latency Reversal by BAFi's is Synergistically Enhanced by Co-
treatment With Prostratin and SAHA
Combination therapy using latency reversal agents (LRAs) targeting
different pathways is considered the most effective strategy for reacti-
vation of latent HIV-1 (De Crignis and Mahmoudi, 2014; Laird et al.,
2015). HDAC inhibitors (HDACi's) and PKC agonists are two promising
classes of compounds currently under clinical investigation for their
potential to reverse HIV-1 latency. HDACi's counteract the activity of
histone deacetylases which repress HIV-1 transcription by compacting
chromatin structure, whereas Prostratin induces translocation of NF-
κB to the nucleus where it binds to the HIV-1 LTR and activates its
transcription. To examine whether the combination of these mecha-
nisms with BAF inhibition would enhance the activation of latent HIV-
1 we evaluated the effect of SAHA and Prostratin after siRNA mediatedknock down of BAF complex or treatment with BAFi's. The Bliss inde-
pendence model for combined drug effects was used to calculate the
threshold for synergism (Bliss, 1939; Zhao et al., 2014a).
J-Lat 11.1 cellswere treatedwith SAHAor Prostratin after nucleofection
with BAF250a-speciﬁc siRNA. siRNA treatment alone induced a lim-
ited activation of HIV-1 LTR as shown by the slight increase in the
percentage of GFP positive cells at 48 h; when BAF250a-depleted
cells were co-treatedwith Prostratin or SAHA, however, we observed
a synergistic or additive, respectively, increase in reactivation of
latent HIV-1 (Fig. 3a). Neither treatment signiﬁcantly affected cell
viability. Notably, we observed a similar effect when BAF complex
activity was inhibited using BAFi's. J-Lat 11.1 cells were treated
with Prostratin or SAHA alone or together with increasing concen-
trations of A01, A11, and C09 ranging from 0.5 μM to 4 μM (Fig. 3b).
C09 demonstrated the most potent activity, synergistically enhanc-
ing HIV-1 transcription with both Prostratin and SAHA at all tested
concentrations, whereas combination of LRAs with either A01 or
A11 induced a synergistic or additive increase in activity depending
on the concentration tested as shown (Fig. 3b). Interestingly, all
BAFi's showed synergism used in triple treatment, i. e. when cells
were treated with a combination of SAHA and Prostratin together
with sub-optimal concentrations of BAFi's (Fig. 3c). We performed
Formaldehyde Assisted Isolation of regulatory Elements (FAIRE) in
order to examine the effect of BAFi's on the positioning of the latent
HIV-1 LTR nuc-1 (Fig. 3d). Consistent with the previously observed
HIV-1 activation and the displacement of BAF250a from DHS-1 and
Nuc-1 demonstrated by ChIP assay, treatment with BAFi's resulted
in a dose dependent remodeling of nuc-1 as demonstrated by
Fig. 2. Treatment with BAFi's speciﬁcally modulates BAF target genes, and displaces the BAF complex from the latent HIV-1 LTR. (Panel a) Knockdown of BAF complex was obtained by
nucleofecting J-Lat 11.1 cells with siRNA targeting the BAF complex speciﬁc subunit BAF250a. RNA levels of BAF250a were quantitated by RT PCR analysis, whereas protein levels of
BAF250a aswell as of the other subunits of the complexwere determined byWestern blot. RT-PCR analysis of J-Lat 11.1 cells after BAF250a knockdown (Panel b) or treatmentwith BAFi's
A01 (1 μM), A11 (1 μM) and C09 (1 μM) for 18h (Panel c). The effect of BAFi's treatmentwasmonitored analyzing the changes in gene expression of HIV-1 LTR driven genes (GFP,GAG) and
BAF target genes (TLR2,MMP9, IFNß, IL6, IL10, SOCS3). A set of BAF independent genes (CYCA2,MIP26, ß-ACTIN, ß-2-MICROGLOBULIN) was used as control. RT-qPCR data are presented as
mean ± SD. (Panel d) BAFi treatment results in displacement of the BAF complex-speciﬁc subunit BAF250a from DHS1 and nuc-1 regions of the HIV-1 LTR. J-Lat 11.1 cells untreated or
treated with BAFi's at indicated concentrations were subjected to ChIP using antibodies speciﬁc for the BAF250a subunit. Input and immunoprecipitated DNA were analyzed by PCR
using primer pairs speciﬁc for the HIV-1 LTR nuc-0, DHS1, and nuc-1 regions and for a control region located upstream of the Axin gene promoter. ChIP results are presented as percent
of immunoprecipitated material over input, error bars represent the standard deviation of three independent experiments. * indicates the level of signiﬁcance at p b 0.05.
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1 (Fig. 3d and Figure S3). Moreover, BAFi-induced remodeling of
nuc-1 was also synergistically enhanced at the molecular level after
co-treatment with Prostratin (Fig. 3d and Figure S3b).
The striking synergism observed when cells were co-treated with
the BAFi C09 and the PKC agonist Prostratin was unexpected, as C09
or Caffeic Acid Phenethyl Ester (CAPE) has been previously described
to be an inhibitor of NF-κB, albeit at signiﬁcantly higher concentrations
(Marquez et al., 2004; Natarajan et al., 1996; Wang et al., 2010). We
therefore examined the activity of C09 in a range of concentrations on
Prostratin-induced IκBα degradation and HIV-1 activation. At concen-
trations effective in latency reversal (0.5–2 μM), C09 did not inhibitIκBα degradation induced by Prostratin (Figure S4a). Moreover, while
synergistic with Prostratin in activation of the latent HIV-1 promoter
at low concentrations, C09 interfered with the ability of Prostratin to
re-activate latent HIV-1 when used at higher concentrations (30–
100 μM) (Figure S4b), consistent with its previously described activity
as an NF-κB inhibitor.
3.3. BAFi's Reverse HIV-1 Latency in Primary Infected CD4+T CellsWithout
Inducing Cell Activation
The main reservoir of latent HIV-1 in infected patients resides in
resting CD4+ T cells. Due to their extended life span and the capacity
Fig. 3.Re-activation of latent HIV-1 by BAF inhibition is synergistically enhancedwith co-treatmentwith HDACi's and PKC agonists. (Panel a) Percent of GFP positive cells was evaluated in
BAF complex depleted J-Lat 11.1 cells 24 and 48 h after treatmentwith suboptimal concentrations of Prostratin and SAHA. (Panel b and c) J-Lat 11.1 cells were treatedwith BAFi's A01, A11
and C09 alone or together with SAHA and-or Prostratin. HIV-1 re-activation was monitored by measuring the percentage of cells expressing GFP: colored bars show the percent of GFP
positive cells after treatment, whereas gray bars show cell viability. (Panel d) Levels of nucleosome occupancy of the HIV-1 5'LTR Nuc-1 region following treatment with BAFi's alone
and in combination with Prostratin were analyzed using FAIRE assay. Data are presented as mean ± SD. The (^) symbol indicates a synergistic interaction between treatments.
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to HIV-1 eradication and are the most relevant target to determine the
activity and efﬁciency of potential LRAs. Therefore, while T cell line
models of HIV-1 latency represent useful models for compound screens
and the initial molecular characterization of putative LRAs that requires
large scale techniques, it is critical that potential LRAs are characterized
also in primary T cell models of HIV-1 latency.
Several primary cell models of HIV-1 latency have been developed
and validated in past years. In this study we ﬁrst tested the activity of
BAFi's using two in vitro primary models that recapitulate two different
mechanisms that are thought to mediate the establishment of HIV-1
latency in vivo (Fig. 4a and b). In the ﬁrst model, initially developed
by O′ Doherty (Swiggard et al., 2005) and further modiﬁed by Lassen
and Greene (Lassen et al., 2012), primary cells are infected without
activation; the lack of speciﬁc transcription factors and the reduced
metabolic rate in resting cells prevents the establishment of a produc-
tive infection and drives the virus into the latent state (Fig. 4a). In
this model, infected cells mainly belong to the Transitional (CD4+
CD45RO+ CCR7- CD27+) and Central Memory (CD4+ CD45RO+
CCR7+ CD27+) populations. In the second method, developed by
Bosque and Planelles, primary CD4+ T cells are stimulated for three
days and infection is performed after removing the activating stimuli,i.e. during reversion to the resting state (Bosque and Planelles, 2009)
(Fig. 4b). Cells generated via thismodel acquire a phenotype that closely
resembles the CD4+ Central Memory population (CD4+ CD45RO+
CCR7+ CD27+), which is thought to harbor the majority of latent
proviruses in HIV-1 infected individuals under suppressive cART
(Chomont et al., 2009). In both protocols, cells were infected with a
defective virus harboring luciferase in place of the envelope gene and
latency reversal activity was monitored determining the levels of
luciferase activity 24 h after treatment with BAFi's.
To verify the activity of BAFi's on latent HIV-1, primary cells were
treated with increasing concentrations of A11 and C09, the two
compounds showing the maximum activity in cell line models of
latency. The range of concentrationswas selected based on their toxicity
proﬁle on primary cells. We observed a dose dependent increase in
luciferase activity after treatment with C09 (Fig. 4c and d) with signiﬁ-
cantly higher levels of luciferase activity compared to untreated control
at 1 μMand 2 μMconcentrations (p b 0.05). Treatmentwith A11 did not
induce signiﬁcant activation of latent HIV-1, however we observed a
tendency towards activation at the highest concentration (10 μM).
CD4+ T cells obtained from virologically suppressed HIV-1 infected
patients are considered the most relevant model system for assessing
the efﬁcacy of potential latency reversal compounds. In light of our
Fig. 4.BAFi treatment re-activates latentHIV-1 in twodistinct primarymodel systems ofHIV-1 latency. Latency reversal activity of theBAFi's A11 andC09was testedon twomodels of HIV-
1 latency. Panel a (Lassen and Greene) and b (Bosque and Planelles) depict the protocols for latency establishment in primary human CD4+ T cells. FACS plots show the characteristic of
the cells population at themoment of reactivation for eachmethod. Dotplots (Panels c and d) show the fold increase in luciferase activity after treatment with different concentrations of
A11 and C09. Each dot represents a single measurement, black horizontal lines show the average fold increase for each treatment. Experiments were performed in duplicate using cells
obtained from 6 healthy blood donors. Panel e shows the levels of cell associated HIV-1 RNA in CD4+ T cells isolated from three virologically suppressed HIV-infected patients after treat-
mentwith the BAFi's C09 and A11. Cells obtained from Patient 1 and Patient 2were further analyzed and treatedwith BAFi's in combinationwith Prostratin (Panel f). Cell associatedHIV-1
RNA was measured as the number of copies of HIV-1 POL per μg of input RNA; for each condition, bars represent the average of experiments performed at least in triplicate. Statistical
signiﬁcance was calculated within patient, based on at least three independent replicates performed for each condition. Asterisks indicate the level of signiﬁcance (* p b 0.05, **
p b 0.01, *** p b 0.001).
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primary ex-vivo infected cells, we sought to conﬁrm these observations
in CD4+ T cells obtained from HIV-1 infected patients. Three patients
who maintained HIV-1 viremia below 50 copies/ml for at least two
years (Pt1 3 years; Pt2 2 years; Pt 3 3 years) were enrolled in the
study. Untouched total CD4+ T cells were puriﬁed from PBMCs and
used to assess the effect of BAFi's on the latent HIV-1 reservoir.
Treatment with BAFi's alone increased the levels of cellular associated
HIV-1 RNA in CD4+ T cells obtained from two out of three patients. In
this model, increase in HIV-1 transcription after BAFi treatment
mirrored the results obtained in the ex vivo infected primary cells:
C09 elicited HIV-1 transcription at 1 μMconcentration, and A11 showed
reversal activity at 20 μM, conﬁrming the trend observed in the ex vivo
infected model (Fig. 4e). A variable response to treatment with de-
repressors in primary cells obtained from HIV-1 infected patients hasbeen observed previously (Archin et al., 2012; Wei et al., 2014; Laird
et al., 2015); however, even in absence of a detectable effect, the remov-
al of a repressive mechanism has been suggested to facilitate triggering
of transcription by enhancing noise and increasing the likelihood of
stochastic promoter activation (Dar et al., 2014). We therefore exam-
ined the effect of the co-treatment of BAFi's together with the PKC
agonist Prostratin on cells obtained from Patients 1 and 2. CD4+ T
cells obtained from Patient 1, which did not respond to BAFi's alone,
and CD4+ T cells obtained from Patient 2, which showed a BAFi-
induced increase in HIV-1 cellular associated RNA, were treated
with BAFi's alone or in combination with a sub-optimal concentration
of Prostratin. As shown in Fig. 4f, treatment with BAFi's enhanced
Prostratin-mediatedHIV-1 transcription, independently of the response
of cells to BAFi treatment alone. In particular, combination treatment
with A11 togetherwith Prostratin resulted in a signiﬁcant enhancement
117M. Stoszko et al. / EBioMedicine 3 (2016) 108–121of Prostratin-induced increase in cellular associated HIV-1 RNA in both
patients. Interestingly, C09, although capable of signiﬁcantly inducing
latency reversal in patient cells when used alone, did not signiﬁcantly
enhance Prostratin-mediated latency reversal, consistent with its role
in NF-κB pathway inhibition. Given this limitation, C09 will likely be
more effective in latency reversal combinations lacking PKC activators.
Taken together, these results showed that treatment with BAFi's either
alone or in combination with Prostratin resulted in latency reversal in
all three patients included in the study.
Activation of bystander uninfected cells is a side effect which can
be observed after treatment with LRAs (DeChristopher et al., 2012;
Korin et al., 2002). Massive stimulation of T cells can result in general
immune activation and thus will decrease the potential usefulness of
latency reversal molecules in clinical settings. To investigate the effect
of BAFi's on primary cells we treated human CD4+ T cells isolated
from healthy donors with A11 and C09 for 72 h, and determined
the levels of T cell activation and proliferation by ﬂow cytometric anal-
ysis of CD25 and Ki67, respectively. Treatment with PMA-Ionomycin
was used as a positive control. As shown in Fig. 5, in contrast toFig. 5.BAF inhibitors donot induce T cell activation or proliferation. Percentage of cells expressin
CD4+ T cells treated with A11 and C09. Treatment with PMA/Ionomycin was used as a positiv
from three healthy blood donors. Images on the ﬁgure shows representative FACS plots for eacPMA, treatment with BAFi's did not induce CD25 (Fig. 5a) and Ki67
(Fig. 5b) expression compared to untreated control during 3 days of
treatment.
3.4. Treatmentwith BAF Inhibitors Prevents Latency Establishment in Jurkat
Cells
We have previously demonstrated that, in addition to its role in
maintenance of HIV-1 latency, the BAF complex also contributes to the
establishment of latency, as siRNAdepletion of BAF subunits signiﬁcant-
ly decreased the incidence of latent infections in T cell lines (Rafati et al.,
2011). We therefore examined whether inhibition of the BAF complex
with A01, A11, and C09 interfered with the establishment of HIV-1
latency.
Jurkat cells were pre-treated with 1 μM A01, A11, or C09 for 30 min
prior to infectionwith an HIV-1 derived virus containing a GFP reporter,
LTR-Tat-IRES-GFP in presence of BAFi's. Percentage of GFP positive cells
and relative amount of integrated DNA were measured ﬁve days after
infection to evaluate infection efﬁciency. GFP-negative cell populationg themarkers of cell activation (CD25, panel a) andproliferation (KI67, panel b) in primary
e control. Bars represent the average ± SD of experiments performed on samples deriving
h marker.
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sorted by ﬂow cytometry and stimulated with PMA. The percentage of
GFP positive, latently infected cells was then determined and quantitate
by FACS analysis (Fig. 6a). While treatment with A01 caused a slight
increase in productive integrations, treatment of cells with A11 and
C09 did not signiﬁcantly affect the percentage of cells productively
infected with the HIV-1 derived virus (Fig. 6b and c). However, when
cells were treated with either A11 or C09, we observed a signiﬁcant
decrease in the percentage of GFP positive cells after PMA treatment,
corresponding to a lower incidence of latent infections (Fig. 6d). Taken
together these data show that inhibition of BAF activity using A11 and
C09 interferes with the establishment of latency.
4. Discussion
Recent pharmacological efforts aimed at HIV-1 eradication have
focused on the development of “shock and kill” strategies, where HIV-
1 is induced from latency in order to render infected cell recognizable
to the immune system for clearance. We showed previously that the
BAF chromatin remodeling complex plays an important role in the
establishment and maintenance of HIV-1 latency, highlighting BAF as
an attractive molecular target in HIV-1 eradication efforts. We have
now tested a panel of small molecules, recently discovered in a screen
for inhibition of BAF activity, for their potential to reverseHIV-1 latency.
Treatment with BAFi's results in activation of latent virus in cell line as
well as primary cell models harboring latent HIV-1. BAFi's constitute a
group ofmolecules including compoundswith different chemical struc-
tures targeting BAF activity with different degrees of speciﬁcity and
potency. In the present screening we found the highest levels of HIV-1
activation for two compounds, A11 and C09.
A11, or Pyrimethamine (PYR), is an FDA approved licensed anti-
protozoan drug which has been used to control opportunistic infections
in HIV-1 infected patients (Rosenblatt, 1999; Klinker et al., 1996;
Mathanga et al., 2011). Consistent with our results describing PYR as
an activator of HIV-1 transcription, a previous report has shown that
PYR, in the 10–100 μM range, can enhance HIV-1 replication in vitro inFig. 6. Inhibition of BAF prevents the establishment of latent HIV+ infections. (Panel a) FACS p
sorted (left panel)ﬁvedays after infections. Following sorting, the GFP-negative population (mid
48 h after reactivation (right panel). (Panel b) Infection efﬁciency in untreated vs BAFi's treate
productive infections) 5 days after infection. (Panel c) Proviral load from the infected populatio
to untreated control. (Panel d) GFP-negative population (containing uninfected as well as latent
itive cells (i.e. latently infected cells) for each treatment. Data are presented as mean ± SD, * inhuman PBMCs (Oguariri et al., 2010). C09, caffeic acid phenetyl esther
(CAPE), is a bioactive compound found in many plants and isolated
from honey bee propolis (Wu et al., 2011) shown to possess anti-
inﬂammatory and immunomodulatory capacities (Tolba et al., 2013).
CAPE, currently under clinical investigation (Clinical trial.gov identiﬁer:
NCT02050334 and NCT02351622), has been proposed in the treatment
of several diseases including thrombocytopenia and cancer. CAPE has
also been shown to function as a non-competitive inhibitor of the en-
zyme HIV-1 integrase and thus inhibits HIV-1 replication (Fesen et al.,
1994). In the 0.5–2 μM concentration range in which CAPE efﬁciently
reactivates latent HIV-1, we did not observe an inhibitory effect on
HIV-1 integration. We did however observe a decreased propensity for
latency establishment in Jurkat cells in presence of low concentrations
of both PYR and CAPE, mimicking decreased latency establishment
upon siRNA mediated depletion of BAF shown previously (Rafati et al.,
2011). The ability of BAFi's to prevent establishment of latency is of
great interest in light of their potential use as LRAs. Indeed, despite
the high efﬁciency of cART, the concentrations of antiretroviral drugs
might not reach the optimal levels in some anatomical compartments.
If reactivation of latent HIV-1 takes place in these compartments, de
novo infections may occur and possibly lead to the establishment of a
new reservoir. The use of LRAs that also inhibit infection and latency
establishment, such as BAFi's and Romidepsin (Jonsson et al., 2015),
could therefore increase the overall safety of latency reactivation
strategies.
One important clinical consideration to be made in evaluating the
potential of candidate molecules for latency reversal is whether they
are able to generate sufﬁcient levels of HIV-1 activation without induc-
ing immune activation. Using two primary cell models of latency, we
found that BAFi's induce reversal of HIV-1 latency in primary CD4+ T
cells, which represent the main target of HIV-1 infection and harbor
the majority of latent virus. Importantly, treatment of primary cells
with BAFi's, at concentrations which efﬁciently induce latency reversal,
did not result in cell proliferation nor caused general activation of
primary CD4+ T cells. We also examined the activity of BAFi's in
CD4+ T cells obtained from three long-term virologically suppressedlots show the protocol for quantiﬁcation of latently infected cells. GFP-negative cells were
dle panel)was stimulatedwith PMAand the percentage of reactivated cellswasmeasured
d samples was determined by FACS. Bars represent the percent of GFP positive cells (i.e.
n was measured by Alu-PCR. Bars represent the relative amount of HIV-1 DNA compared
ly infected cells) was treatedwith PMA for 48 h. Bars represent the percentage of GFP pos-
dicates the level of signiﬁcance at p b 0.05.
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relevantmodel of latency. Thepatients included in our studywere treat-
ed for at least 3 years and showed no sign of viral replication for at least
2 years. In fully suppressed c-ART treated patients, the presence of HIV-
1 in activated T cells has been shown to be negligible (Finzi et al., 1997).
To assess BAFi-mediated latency reversal, we therefore used total CD4+
patient T cells that include both activated and resting T cells as a surro-
gate for resting CD4+T cell response, an approach also used in other re-
cent studies to examine latency reversal ex vivo (Wei et al., 2014; Jiang
et al., 2014, 2015).
In Patient 2 and 3, treatmentwith BAFi's alone increased the levels of
cellular associatedHIV-1 RNA. Although limited, the two fold increase in
HIV-1 cellular associated RNA levels observed is similar to the modest
effects of BAFi treatment alone observed in both cell line models and
in vitro infected primary cells, and is consistent with de-repression,
which results from removal of an LTR-bound repressive complex.
Similar levels of activity have been observed for other candidate LRAs
such as Vorinostat, Disulﬁram, JQ1, and Romidepsin (Jiang et al., 2014;
Laird et al., 2015; Wei et al., 2014). Importantly, many of the putative
LRAs which showed limited latency reversal activity when used alone,
have been shown to effectively induce HIV-1 transcription when used
in combination (Laird et al., 2015; Spivak et al., 2015; Barton et al.,
2014). Similarly, in cells obtained from both Patient 1, in which treat-
ment with BAFi's alone did not upregulate the levels of HIV-1 RNA,
and Patient 2, which responded to BAFi treatment, co-treatment using
PYR together with the bona ﬁde activator Prostratin resulted in signiﬁ-
cant enhancement of Prostratin mediated HIV-1 activation.
Interestingly, although CAPE when used alone induced signiﬁcant
latency reversal in cells from two of the three patients examined, it
did not result in signiﬁcant enhancement of Prostratin-mediated laten-
cy reversal. This lack of synergy is likely due to the described effect of
CAPE in inhibition of NF-κB. At high concentrations (10–85 μM) CAPE
has been shown to block phosphorylation and degradation of IκB
(Zhao et al., 2014b; Wang et al., 2010; Shvarzbeyn and Huleihel,
2011), and to inhibit translocation and DNA binding of p65 (Natarajan
et al., 1996; Marquez et al., 2004). It is noteworthy that, in our experi-
mental setting, CAPE was effective in activating latent HIV-1 at concen-
trations ranging from0.5 to 2 μM.At these relatively low concentrations,
CAPE showed signiﬁcant synergy in latency reversal and did not show
an inhibitory effect towards either Prostratin-induced activation of
latent HIV-1 or Prostratin-mediated degradation of IκB in cell lines.
The difference between cell line and patient cell response to CAPE in
latency reversal highlights the importance of validation of potential
LRA activity in primary cells.
Another clinical consideration in appraising the potential for candi-
date LRAs, is the question of target speciﬁcity; most LRAs currently
under investigation target chromatin modifying factors or transcrip-
tional pathways, which are essential for normal regulation of host
gene expression. Targeting these complexes will therefore have pleio-
tropic consequences and result in mis-regulation of host gene expres-
sion as it was recently shown for SAHA (Elliott et al., 2014). Similarly
to SAHA, treatment with BAFi's, particularly at high concentrations,
may result in adverse pleiotropic effects, including induction of genes
counteracting HIV-1 activation (White et al., 2015). Further studies,
such as transcriptome and proteome analysis, are needed to determine
the array of cellular modiﬁcations induced by these compounds. In
this context, inclusion of distinct LRAs, which function via different
molecular targets in a combination therapy, would decrease the adverse
pleiotropic effects of each compound, decrease toxicity issues, and
provide a higher degree of speciﬁcity for the HIV-1 LTR.
Transcription of integrated HIV-1 is stochastic, and reversal of the
latent state using a single agent canbe limited by speciﬁc factors, includ-
ing restrictions posed by the site of integration of the virus and its
molecular environment, subtypes of the latent virus and their suscepti-
bility to a single agent, and the cell type in which latency is established.
Data obtained from in vitro cell line HIV-1 latency models support theeffectiveness of combinatorial approaches for the synergistic activation
of HIV-1 transcription. These synergistic effects are likely the result of
the combination of two mechanisms: the removal or decrease in a
repressive chromatin environment together with the triggering and
recruitment of bona ﬁde activators. Combination of Prostratin with
HDACi's results in synergistic activation of HIV-1 in vitro (Reuse et al.,
2009; Ying et al., 2012; Qu et al., 2013; Burnett et al., 2010; Pandeló
et al., 2014; Micheva-Viteva et al., 2011) as well as ex vivo (Laird
et al., 2015). Similarly, BAFi-mediated reversal of transcriptional latency
was synergistically enhanced when latent cells were co-treated with
the HDAC inhibitor SAHA or the PKC agonist Prostratin. FAIRE assays
indicate remodeling of the repressive LTR nuc-1 in response to BAFi
treatment at the molecular level, and demonstrate the molecular
synergism between Prostratin and BAFi's leading to eviction of nuc-1.
These ﬁndings point to the importance of combining molecules that
target multiple pathways to disrupt and reverse the latent transcrip-
tional state of the virus in shock and kill strategies.
Our data highlights the potential of BAFi's as a source of molecules
for inclusion in latency reversal therapies. BAFi's effectively reverse
latency either alone or in combination with Prostratin in all three
patients enrolled in this study. A caveat of the current study is the lim-
ited number of patients enrolled, which does not allow for a strong
statistical validation of the effect of BAFi's across patients. Nevertheless,
although not sufﬁcient to fully recapitulate the variability in response to
LRAs across patients, the data from the three included patients support
our observations in cell lines and other primary models of latency.
As with other molecules currently under clinical characterization in
latency reversal, it is conceivable that with BAF inhibitors too, there
will be some variability in patient response. Thus ex vivo studies per-
formed on a larger number of HIV-1 infected patients are required in
order to statistically validate the present observations. These studies, to-
gether with proof-of-concept clinical studies are the necessary next
steps in order to further characterize the potency and applicability of
BAFi's to reverse the latent HIV-1 reservoir in vivo. Given their demon-
strated promising activity and the available information concerning
their toxicity and pharmokinetics proﬁles, CAPE and PYR, represent at-
tractive candidates for future clinical development. Further screenings
will likely identify additional molecules targeting HIV-1 latency via
counteracting the activity of the repressive BAF complex. Importantly,
since targeting a previously unexplored pathway, this promising class
of drugs has high potential for inclusion in combination therapy.Funding Source
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